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Background
Infants of women infected with HIV-1 are born with anti-
bodies specific for the virus. In the non-human primate
model, neutralizing antibodies (NAb) protect from SHIV/
SIV transmission, implying a role for such a response in
candidate HIV vaccines. The setting of mother to child
HIV transmission provides an opportunity to examine
whether NAb provide protection from HIV infection in
exposed humans.
Methods
Heterologous NAb breadth and potency were measured in
week 0-1 postpartum plasma from breast-feeding infants
(N = 104) born to women with HIV-1 using pseudovi-
ruses incorporating envelopes from 8 different variants in
a single cycle infection assay. The plasma concentration
inhibiting 50% of virus (IC50) was determined for each
virus/plasma pair and breadth/potency scores were
defined. These were compared using the Mann-Whitney U
test. A multivariate logistic regression model including
maternal CD4 and viral load was used to determine the
odds of infection and a Cox proportional hazards model
was used to determine the impact of NAb potency and
breadth on time to infection.
Results
In case-control analysis, the IC50 did not differ between
infants who were or were not infected in the first 1.5 (n =
22), 6 (n = 25) or 24 months (n = 38) (p > 0.5 for each
test). Potency (p = 0.7) and breadth (p = 0.49) of response
did not differ between cases/controls. Neither potency nor
breadth was associated with odds of infant infection
(OR~1, p > 0.5). In cohort analysis, maternal viral load
had the largest impact on time-to-infection (HR = 1.97, p
= 0.011), but neither neutralizing breadth nor potency
appeared to play a role (HR = 1, p = 0.5).
Conclusion
In this study of 104 infants at risk for breastfeeding HIV
transmission, neither potent nor broad heterologous neu-
tralizing antibodies affected transmission risk. These
results suggest that the breadth of the antibody response,
as defined by neutralization of a heterologous virus panel,
does not predict protection from mother to child trans-
mission.
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